Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Integrative analysis of the interplay between peripheral immune landscape and leukemic blast adaptation in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEla CerovskáDKDávid KundrátPSPavla Suchánková

Discussion

Loading...

Member takes

Overview

Findings reveal immune surveillance impacts gene expression and clinical outcomes in Acute Myeloid Leukemia, suggesting immune modulation roles.

Key Points

  • High lymphoid cytotoxic cell fraction correlates with improved clinical outcomes in Acute Myeloid Leukemia patients.
  • Gene expression analysis highlighted immune evasion mechanisms and tumor suppressor gene activity in leukemic blasts.
  • This observational analysis integrated immune profiles with gene set enrichment findings from leukemic samples.
  • These insights may inform new strategies for immunotherapeutic approaches in treating Acute Myeloid Leukemia.

Cite This Study

Cerovská et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da0fhttps://doi.org/10.1182/blood-2025-3486
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia2025
  2. 2Comprehensive profiling of the bone marrow microenvironment reveals an exhausted immune signature associated with tumor burden in Acute Myeloid Leukemia2025
  3. 3Functional plasma cell signatures mark AML chemotherapy responders: Evidence from immune niche profiling2025
  4. 4The Acute Myeloid Leukemia microenvironment is defined by ineffective immune surveillance despite the presence of activated, clonally-expanded CD8 T cells with preserved effector function2025
  5. 5Deciphering the bone marrow inflammatory cytokine network in AML prognosis and immune evasion: A focus on the IL-1A-CCL3/4 axis as a novel therapeutic target2025